BusinessOcera Therapeutics Announces Presentation of Two Preclinical Studies Further Supporting Its Ammonia Scavenger OCR-002 at The International Liver Congress™ 2016 of the European Association for the Study of the Liver (EASL)By Nasdaq OMXApr 15, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Announces Publication of Promising Preclinical Data in Support of Its Ammonia Scavenger OCR-002 in the Journal of HepatologyBy Nasdaq OMXApr 11, 2016, 1:05 PM UTC
BusinessOcera Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate UpdateBy Nasdaq OMXMar 3, 2016, 2:05 PM UTC
BusinessOcera to Present at the Cowen and Company 36th Annual Health Care ConferenceBy Nasdaq OMXFeb 29, 2016, 9:05 PM UTC
BusinessOcera to Present at the 18th Annual BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 2, 2016, 9:20 PM UTC
BusinessOcera Announces Complete Plasma Data From Pilot Phase 1 Study for Orally-Available OCR-002 in Development for the Prevention of Chronic Hepatic EncephalopathyBy Nasdaq OMXJan 8, 2016, 2:05 PM UTC
BusinessOcera Appoints Dr. Stan Bukofzer as Chief Medical OfficerBy Nasdaq OMXJan 7, 2016, 9:05 PM UTC
